Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase

INTRODUCTION: Childhood chronic myeloid leukemia (CML) accounts for less than 3% of all childhood leukemias, hence, data on imatinib (IM) in adult CML patients has been largely extrapolated to children. We have analyzed our data to add to the existing literature. AIMS: Primary objective is to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Linga, Vijay Gandhi, Ganta, Ranga Raman, Kalpathi, Krishnamani Iyer, Gundeti, Sadashivudu, Rajappa, Senthil J., Digumarti, Raghunadharao, Paul, Tara Roshni, Tandon, Ashwani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
LEUKEMIAS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236696/
https://www.ncbi.nlm.nih.gov/pubmed/25422804
http://dx.doi.org/10.4103/2278-330X.142961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236696/
https://www.ncbi.nlm.nih.gov/pubmed/25422804
http://dx.doi.org/10.4103/2278-330X.142961

Ejemplares similares